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and Angioedema
Japanese Guidelines for Diagnosis and
Treatment of Urticaria in Comparison
with Other Countries
Michihiro Hide1 and Takaaki Hiragun1
ABSTRACT
Several guidelines for urticaria and angioedema have been published in Europe and United States since 1997.
General principles for diagnosis and treatments of them are similar. However, each guideline has its own char-
acteristics and shows differences in areas such as the coverage of urticaria subtypes, nomenclatures, and hier-
archy of the medications. In Japan, the Japanese Dermatological Association (JDA) published its first guideline
for urticaria and angioedema in 2005. It established a new classification of urticaria and angioedema together
with the definition of each subtype. It emphasized the importance of discriminating idiopathic urticaria, consist-
ing of acute urticaria and chronic urticaria from inducible urticaria, such as allergic urticaria, physical urticaria
and cholinergic urticaria. It contains several unique algorithms for diagnosis and treatment of urticaria from a
view point of clinical practices, and was further enforced by a style of EBM in 2011. Nevertheless, these guide-
lines have not been recognized outside of Japan, because of a language barrier. In this article, the outline of
the newest guidelines by JDA are introduced and compared with the guidelines in other countries published in
English.
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INTRODUCTION
Urticaria is one of the most common skin diseases
and the management of this disease is an important
issue in daily activities for many physicians. Urticaria
is characterized by the appearance of itchy wheals
and flare that usually disappear in hours. The diagno-
sis of urticaria itself is easy because of its characteris-
tic clinical symptoms. Vascular dilatation, increase of
vascular hyper-permeability and the activation of itch-
sensory nerve system are the histopathological reac-
tions that develop clinical symptoms observed in urti-
caria. It has been widely accepted that these reac-
tions are induced by mast cell degranulation in the
skin and antihistamines are the mainstay for the treat-
ment of urticaria. However, the pathogenesis behind
mast cell degranulation is largely unknown and the
treatment for urticaria refractory against antihista-
mine has been controversial. The European Academy
of Allergy and Clinical Immunology (EAACI), Global
Allergy and Asthma European Network (GA2LEN),
and European Dermatology Forum (EDF) published
their first guideline in 20061,2 and revised it with
World Allergy Organization (WAO) in 2009.3,4 On the
other hand, Japanese Dermatological Association
(JDA) published a comprehensive guideline for the
treatment of urticaria and angioedema in Japanese in
2005.5 It was incorporated into two other Japanese
guidelines, one for primary care in 20076 and another
for general physicians by Japanese Society of Aller-
gology (JSA) in 2009.7 In this article, we introduce
the contents of the newest version of the JDA guide-
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Table　1　Guidelines for urticaria and their authorizing organizations published in English or Japanese
1997 Physical urticaria: classifi cation and diagnostic guidelines9)
European Academy of Allergology and Clinical Immunology (EAACI) Subcommittee on Allergic Skin Diseases
2000 The diagnosis and management of urticaria10)
Joint Task Force on Practice Parameters (AAAAI, ACAAI, JCAAI)
2001 Management and diagnostic guidelines for urticaria and angio-oedema11)
British Association of Dermatologists (BAD)
2005 Guidelines for the diagnosis and treatment of urticaria and angioedema5)
Japanese Dermatological Association
2006 EAACI/GA2LEN/EDF guidelines: defi nition, classifi cation and diagnosis of urticaria1), and management of urticaria2)
EAACI/GA2LEN/EDF
2007 AAITO Committee for Chronic Urticaria and Pruritus Guidelines12)
Associazione Allergologi Immunologi Territoriali Ospedalieri 
2007 BSACI guidelines for the management of chronic urticaria and angio-oedema13)
British Society for Allergy and Clinical Immunology (BSACI)
2007 Guidelines for evaluation and management of urticaria in adults and children14) (revised)
British Association of Dermatologists (BAD)
2007 Primary care version of guidelines for the diagnosis and treatment of urticaria and angioedema6)
Research group supported by Japanese Ministry of Health, Labour and Welfare
2009 EAACI/GA2LEN/EDF/WAO guidelines: defi nition, classifi cation and diagnosis of urticaria,3) and management of urticar-
ia4) (revised)
2010 Urticaria and angioedema in Japanese guidelines for the diagnosis and treatment of allergic diseases 20107)
Japanese Society of Allergology
2011 JDA guidelines. Guidelines for the diagnosis and treatment of urticaria8) (revised)
Japanese Dermatological Association
lines published in 2011,8 and compare it with other
guidelines published in English.
INTERNATIONAL GUIDELINES FOR URTI-
CARIA
The first document that described of urticaria with
the term “guideline” and was published in English
was a position paper by EAACI in 1997.9 It dealt with
classification and diagnosis of physical urticarias. In
2000, an American joint task force group published
guidelines specific for acute and chronic urticaria and
angioedema.10 These two documents did not cover
the whole spectrum of clinical practices for urticaria,
including spontaneously occurring type urticaria and
inducible type urticaria. The first document that cov-
ered a wide spectrum of urticaria and angioedema ob-
served in general practices was published by Grattan
et al., on behalf of British Association of Dermatolo-
gists (BAD).11 Following these publications, various
organizations in Europe published guidelines for the
diagnosis and treatment of urticaria and angioedema
(Table 1).1-4,11-14 The second version published by the
EAACI group was approved by several organizations
of allergy and dermatology, and was probably the
most widely accepted in the world.3,4 Moreover, lit-
eratures for unmet clinical needs in chronic spontane-
ous urticaria were extensively reviewed with the best
available information from the literature by GA2LEN
task force group in 2011.15 However, many of the re-
cently published guidelines mainly dealt with the
management of spontaneously occurring urticaria,
the most common type of urticaria encountered in
general medical practices. As a result, however, phy-
sicians may not obtain the full information for prac-
tices relating to other important types of urticaria,
such as urticaria due to type I allergy, cholinergic ur-
ticaria, and physical urticarias.
The first Japanese guideline for the diagnosis and
treatment of urticaria and angioedema was published
in 2005 by JDA.5 This guideline has established the
notion of “idiopathic urticaria”, which is same as
“spontaneous urticaria” in recently published guide-
lines by EAACI and related organizations.1-4 The sec-
ondary important characteristic of this guideline is
the comprehensibility in terms of the classification of
urticaria. It covers most of the clinical subtypes of ur-
ticaria and angioedema for diagnosis and treatments.
Moreover, it was enforced with a chapter consisting
of a first section of clinical questions and a second
section of structured abstracts based on evidence-
based-medicine by a revision in 2011.8
OUTLINES OF JAPANESE GUIDELINES FOR
THE MANAGEMENT OF URTICARIA
The Japanese guideline for diagnosis and treatment
of urticaria published by JDA in 2011 consists of two
chapters: Chapter one comprehensively described
the diagnosis and treatment of urticaria, and chapter
Japanese Guidelines for Urticaria
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Table　2　Factors that may be associated with the pathogenesis of urticaria
1. Direct triggers (mainly exogenous and transient)
1) Exogenous antigens
2) Physical stimuli
3) Sweating
4) Foods†
Food antigens, food histamine, pseudo-allergens (pork, 
bamboo shoot, rice cake, spices, etc.), food additives 
(preservatives, artifi cial pigment), salicylic acids†
5) Drugs
Antigens, contrast media, NSAIDs†, preservatives, suc-
cinic acid esters, vancomycin (red man syndrome), etc.
6) Exercises
2. Backgound factors (mainly endogenous and continuous)
1) Sensitization (specifi c IgE)
2) Infections
3) Tiredness/stress
4) Foods, except for antigens
5)  Drugs 
Aspirin†, other NSAIDs† (for FDEIA), angiotensin con-
verting enzymes (ACE) inhibitors† (for angioedema), etc.
6)  Autoantibodies against IgE or the high affinity IgE recep-
tors
7) Underplaying disease
Collagen and related disease (SLE, Sjögren’s syndrome,
etc.), lympho-proliferating diseases, hereditary disorders 
(e.g. C1-INH defi ciency), serum sickness, other organ 
dysfunctions, circadian rhythm (idiopathic urticaria tends 
to aggravate from evening toward morning)
†May act as either direct triggers or background factors. 
Cited from reference 8.
two consists of 34 clinical questions and 179 struc-
tured abstracts with answerscomments for them.
The outline of this guideline is described below.
DEFINITION AND DIAGNOSIS
Urticaria is a disease that pathologically develops
wheal(s), a transient and localized edema accompa-
nied by flare and, in most cases, itch. Deep and local-
ized edema(s), which may appear by itself or to-
gether with superficial wheals, are particularly called
as angioedema.
The diagnosis of urticaria is made mostly by de-
tailed history taking and visual observations of the
skin. It is important for physicians to correctly diag-
nose subtypes of urticaria, because treatments and
or patients’ behavior vary among subtypes of urti-
caria. Moreover, two or more subtypes of urticaria
may complicate a particular patient at the same time.
Physicians should first make clear at the diagnosis of
urticaria, if it occurs spontaneously or is induced by
specific stimuli. In cases of anaphylactic shock and
or suffocation, actions such as adrenalin injection or
airway management should be taken as necessary.
Clinical examinations are not necessary for all cases,
but may help to establish a solid diagnosis, especially
for cases of inducible type urticaria.
FACTORS ASSOCIATED WITH THE PATHO-
GENESIS OF URTICARIA
Cause is a most frequently and strongly asked ques-
tion in clinical practices for urticaria. The mechanism
of urticaria developed by type I allergy is relatively
simple and antigen should be identified as a cause in
this type of urticaria. However, the involvement of ex-
ogenous andor endogenous factors to develop urti-
caria, especially those with spontaneously occurring
wheals, is not so straightforward. Moreover, any rela-
tion to factors, which have been known as potential
causes of urticaria, may not be apparent in many
cases of urticaria, especially those with spontaneously
occurring wheals. On the other hand, individual pa-
tients may suffer from multiple types of urticaria and
be simultaneously affected by various factors to in-
duce or aggravate symptoms to variable degrees.
Therefore, the question to find a cause itself may not
be adequate in certain cases of urticaria. The 2011
JDA urticaria guideline has listed two groups of fac-
tors, which may be involved in the pathogenesis of
urticaria, one that may directly act or trigger the de-
velopment of urticaria, and another that indirectly
acts to develop urticaria as underlying causes (Table
2).
CLASSIFICATIONS
The 2011 JDA urticaria guideline classified urticaria
into four groups and 16 subtypes (Table 3). The “idi-
opathic urticarias” is a group of urticarias, that daily
and spontaneously develop wheals. The group con-
sists of acute urticaria and chronic urticaria, in which
wheals occur for not less than 1 month or less than 1
month, respectively.
In Japan, the name of “chronic urticaria” is used to
represent, on some occasions, urticaria that contin-
ues to occur for more than one month regardless of
the presence of triggers. However, since the publica-
tion of the first guideline for urticaria by JDA in 2005,
the use of “chronic urticaria” and “acute urticaria”
has been confined to urticaria characterized by spon-
taneously occurring wheals. In this sense, chronic ur-
ticaria defined in the guidelines by JDA is identical to
“chronic spontaneous urticaria” defined in the global
guidelines.1-4
Another characteristic of the JDA classification is
that it also covers subtypes induced by the mecha-
Hide M et al.
520 Allergology International Vol 61, No4, 2012 www.jsaweb.jp
Table　3　Subtypes of urticaria
1. Idiopathic urticaria
1) Acute urticaria
2) Chronic urticaria
2.  Inducible urticaria (Urticaria inducible by particular stimuli 
or conditions)
3) Allergic urticaria
4) Food-dependent exercise-induced anaphylaxis
5) Non-allergic urticaria
6) Aspirin urticaria (urticaria due to intolerance)
7)  Physical urticarias (Mechanical, cold, solar, heat, de-
layed pressure, aquagenic, and vibrative urticarias)
8) Cholinergic urticaria
9) Contact urticaria
3. Angioedema
10) Idiopathic angioedema
11) Exogenous substances-induced angioedema
12)  Angioedema due to C1esterase-inhibitor (C1-INH) im-
pairments (Hereditary angioedema; HAE), autoimmune
angioedema, etc.)
4. Urticaria-related diseased
13) Urticaria vasculitis
14) Urticaria pigmentosa
15) Schnitzler’s syndrome
16) Cryopirin-associated periodic fever (CAPS)
Cited from reference 8.
nism of type I allergy. Food-dependent exercise-
induced anaphylaxis and contact urticaria are, or may
be, induced by type I allergy, but categorized as inde-
pendent subtypes in the guideline, because the treat-
ments and managements for patients with these urti-
carias are substantially different from patients with
other type I allergies.
EXAMINATIONS
There are two aims of clinical examinations for urti-
caria. One is to make a solid diagnosis, and the other
one is to explore causes of the disease. They may
vary according to subtypes of urticaria, suspected by
clinical observations. In general, the former may be
important for urticaria developed by type I allergy
and physical urticarias. On the other hand, the latter
may be more important for idiopathic urticaria. Clini-
cal examinations that may be taken for urticaria sub-
types are listed in Table 4.
TREATMENTS
General Principles
There are two principles for treating urticaria; the
first one being to remove or avoid causes andor ag-
gravating factors of urticaria, and the second one be-
ing to use medications, including antihistamines. The
former is more important than the latter in the man-
agement of inducible types of urticaria, whereas the
latter is more important in spontaneously occurring
urticaria (Fig. 1).
Another important message of this algorithm is
aims of the treatments for urticaria. Namely, the first
one is to achieve a symptom-free condition by con-
tinuous use of medications as the first stage, and the
second one is to achieve both symptom and drug-free
condition, as the final stage.
The third point for the treatment is the balance of
disease severity and burdens of the treatments. The
guideline classified disease severities of urticaria into
six levels with necessities of further treatments (Ta-
ble 5).
Regarding medications for the treatment of urti-
caria, it is widely accepted that oral antihistamines
may be used as a mainstay for virtually all subtypes of
urticaria. However, the efficacies of medications in-
cluding antihistamines on urticaria are largely vari-
able among subtypes, or individuals. Therefore, the
aims and nature of the treatment for urticaria should
be planned, taking into the subtype and severity of ur-
ticaria as well as specific conditions of individual pa-
tients.
Medications
Many of the studies about pharmaceutical treatments
for urticaria have been conducted for idiopathic urti-
caria and angioedema. Medications for idiopathic ur-
ticaria have been classified into four steps in the Japa-
nese guidelines (Fig. 2). The first one is the use of
standard dose of antihistamines among a list of non-
or low-sedative antihistamines in Figure 4. If it is not
sufficiently effective, change to other antihistamines
or an increase up to twice the dose of non- or low
sedative antihistamines are recommended (recom-
mendation level B-C1, evidence level II, V). The medi-
cations grouped in the second step, as supplementary
treatments, include histamine H2-receptor antago-
nists, antileukotrienes, extracts of inflammatory rab-
bit skin inoculated with vaccinia virus, glycyrrhizinic
acid, dapsone, anti-anxiety drugs, tranexamic acid,
and Chinese herbs. The third step is the use of ster-
oid equivalent to 5-15 mgday prednisolone. The
fourth step includes immunological treatments, such
as ciclosporin, and prednisolone at 20 mgday or
more. The fourth step treatments are still experimen-
tal, and may be tried only if symptoms are very se-
vere and refractory. Treatments to take after full sup-
pression of symptoms are indicated in Figure 3.
Medications for other subtype of urticaria were de-
scribed in the original guideline,8 but have not been
included in the present article, because of the limited
space. Most of them are, however, included in step 1
and 2 for idiopathic urticaria.
Cope with Causative andor Aggravating Fac-
tors
Contributions of causative andor aggravating factors
to the pathogenesis of urticaria are largely variable.
Japanese Guidelines for Urticaria
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Table　4　Subtypes of urticaria and aims of clinical examinations
Subtypes Aims of clinical examinations
Idiopathic urticaria
Explore background and aggravating factors: Examinations should be done when involvement of 
factors are suspected by history, physical examination, etc.. No examinations are recommended if 
no apparent symptom except for urticaria was identifi ed. Autologous serum skin test may prove 
the involvement of autoimmune mechanisms in a population of chronic urticaria.
Allergic urticaria
Food-dependent exercise-
induced anaphylaxis
Find causative antigen: Demonstration of specifi c IgE by prick test, serum test, such as immuno-
Cap.
Non-allergic urticaria No commonly recommended examination. Should be diagnosed according to the history of pa-tients.
Aspirin urticaria Identifi cation of causative drug: Prick test with suspected drug to rule out the mechanism of type I allergy. Challenge with small amounts of suspected drug.
Physical urticarias Examination for solid diagnosis: Challenge with physical stimuli suspected by history of patients, if necessary.
Angioedema
Decide subtype, explore cause and/or background factors: Examinations should be taken based 
on history of patients, as those for superfi cial urticaria (idiopathic and inducible). Measure C3, C4, 
CH50 and C1-INH activity when C1-INH defi ciency was suspected without complication of superfi -
cial urticaria.
Urticaria vasculitis Examination for solid diagnosis: Peripheral blood test (increase of CRP, WBC, and decrease of complements), skin biopsy to reveal pathological fi ndings of vasculitis.
Urticaria pigmentosa Examination for solid diagnosis: Scrub skin lesion (Darier’s sign), skin biopsy to reveal accumula-tion of mast cells.
Schnitzler’s syndrome Examination for solid diagnosis: Peripheral blood test (increase of CRP, monoclonal IgM, WBC),skin biopsy to possibly reveal pathological fi ndings of vasculitis (not in all cases).
Cryopirin-associated pe-
riodic fever (CAPS)
Examination for solid diagnosis: Peripheral blood test (increase of CRP, SAA, WBC) skin biopsy
to reveal possibly reveal pathological fi ndings of vasculitis (not in all cases), analysis of cryopirin
gene, CIAS1.
Cited from reference 8.
Fig.　1　Subtype classifi cation and principles of the manage-
ment of urticaria in the Japanese guideline by JDA in 2011.
Cited from reference 8.
Diagnosis of disease subtype
Drug therapies for symptoms
䋨e.g. anti-histamines䋩
Remove or avoid
Causes/aggravating factors
Inducible
urticaria
No symptoms under treatments
No symptoms without treatments
Spontaneous
urticaria
Make clear the aim and options of treatments
In general, pharmaceutical treatments are more im-
portant than extensive examinations to find a particu-
lar cause in the treatment of idiopathic urticaria. How-
ever, it is certainly important to find and avoid factors
associated with urticaria, especially when medica-
tions are not effective. On the other hand, symptoms
of urticaria induced by specific triggers, such as aller-
gic urticaria induced by specific antigen, or non-
allergic one in response to particular drug, cannot be
suppressed in the presence of the stimuli.
Hardening and Tolerance
Although a principle to manage inducible type urti-
carias is to avoid stimuli andor aggravating factors
for symptoms, continuous loading of such factors
may reduce the level of reaction. These effects, called
as hardening or tolerance, may be induced in sub-
types of urticaria with type I allergy, solar urticaria,
cold urticaria, heat urticaria, and cholinergic urti-
caria, especially those with hypohidrosis, but may not
be in mechanical urticaria.
Algorithms for Acute and Chronic Urticaria
If the episode of urticaria symptoms appeared just
once and was not very severe, it is not necessary to
treat with medication. Urticaria that appeared for a
few days or more should be treated with antihista-
mines for 4-5 days to prevent the appearance of fur-
ther symptoms. If such treatments failed to suppress
symptoms, patients should be treated according to
Hide M et al.
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Table　5　Urticaria severities and necessities of the treatment for cases refractory to antihistamines
Level of 
severity Symptoms
Necessity of adding and/or changing to other 
treatments Aim of the treatment
6 Shock or similar to shock Must Regulation of the symp-
toms down to levels 45 Cannot manage a social life High
4 Manage to live with large difficulties
3 Tolerable but uncomfortable
2 Mild symptoms
1 Symptom is not recognized
Cited from reference 8.
Depends on QOL, appearance or possibility of 
the side effects of treatments, cost and 
favorite of the patients, 
etc. 
Remission of the symp-
toms by
treatments
Gradual withdraw and 
stop medicationsLow
Fig.　2　Treatment steps for idiopathic urticaria in the Japanese guideline by JDA 
in 2011. Cited from reference 8.
†Off label use.
‡If prompt improvement is required.
1. Anti-histamines
2. Supplementary medications‡
3. Steroids
4. Experimental trials
e.g. H2-blockers†, anti-leukotrienes†, extracts of inflammatory
rabbit skin inoculated with vaccinia virus, glycyrrhizinic acid,
dapsone, anti-anxiety drugs, tranexamic acid
1. standard doses, 2. change drugs, 3. increase doses
immunological treatments (e.g. CisA†, corticosteroids, 
equivalent >20 mg/day)
corticosteroids, equivalent to 5-15 mg/day prednisolone
the algorithm for chronic urticaria. Very severe cases
with eruptions covering 30% or more of the body sur-
face may be treated by a short use of systemic steroid
(recommendation level C1, evidence level IV).
Treatment of chronic urticaria should be started
with an antihistamine for two weeks following correct
diagnosis and planning of the therapy. If symptoms
disappeared or subsided, the same treatment should
be continued (recommendation level B, evidence level
II) for 1-2 months, and then doses of the antihista-
mine should be decreased gradually. The period of
proactive treatment with an antihistamine after the
complete disappearance of the symptoms are tenta-
tively recommended as 4-7 days for urticaria with a
history within 4 weeks, 1 month for urticaria lasted
for 1-2 months, and 2 months for urticaria lasted for 2
months or longer (recommendation level C1, evidence
level VI) (Fig. 3).
Angioedema
The 2011 JDA urticaria guideline classified angioe-
dema into three subtypes. Idiopathic angioedema and
exogenous factor-induced angioedema should be
treated according to the treatment for idiopathic urti-
carias and inducible type urticarias, respectively. Un-
like the treatment of chronic urticaria, the effect of
tranexamic acid has been endorsed for angioedema
by several clinical studies (recommendation level B,
evidence level II). Moreover, specific treatments are
required for cases with deficiency of C1-inhibitor (C1-
INH).16
Overall Algorithm for Urticaria
The overall practices for urticaria have been summa-
rized in an algorithm shown in Figure 4. Since the im-
portance of actions to take in each subtype is not
same, but partially overlaps, it is important for physi-
cians to comprehensively understand the whole pic-
Japanese Guidelines for Urticaria
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Fig.　3　Algorithm for idiopathic (spontaneous) urticaria in Japanese guideline by JDA in 2011. Cited from reference 8.
Acute Urticaria
*take into account the time
to symptoms free, kinds
and amounts of oral
medications, etc.
Chronic Urticaria
Symptoms
disappeared or
improved  
Yes
No Change to otherdrugs, or consider to
increase the level
of treatment (Fig. 2)
Oral antihistamines
(1~2wks)
Any symptoms in
the course? 
Any symptoms
upon intake every
three days? 
Medication free
or on demand 
Finish treatment or
Follow up  
Benefits overcome
disadvantages, such as
adverse effects, costs. 
No
Yes Step up to
treatments in Fig.2.
Stop
medication
Symptom-free or
remitting?
Continue treatment 
for further
a few days to a week
Treat as same as
chronic urticaria
Confirm
diagnosis
Diagnose and confirm 
objectives in treatment
Reduce
medications by every
few weeks 
Continue the
same treatment
for 1~2 months* 
Continue present treatment
No
No
No
Yes
Yes
Yes
Yes
No
No
No
Yes
Yes
Yes
Any symptoms in
the course? 
Any symptoms in
the course? 
Any symptoms in
the course? 
Finish treatment or
Follow up  
Any symptoms for
a few days? 
No
Oral antihistamines
(5-6 days)
ture of urticaria and continue the treatment until a so-
lution to all problems for each patient is achieved.
EBM FOR URTICARIA
The second chapter of the 2011 JDA urticaria guide-
line consists of two chapters; first for 34 clinical ques-
tions with levels of recommendation and evidence,
and second for 179 structured abstracts. In this pa-
per, questions and titles of the abstracts are listed in
Table 6, 7, respectively.
QUESTIONS TO BE SOLVED
DEFINITION OF CHRONIC URTICARIA
Although a classification of urticaria has been pub-
lished in the guideline by three European organiza-
tions, EAACI, GA2LEN, and EDF,1 and later together
with WAO,3 the definition of chronic urticaria re-
mains vague. A “Joint Task Force on Practice Pa-
rameters” which represented several American socie-
ties10 and the “AAITO Committee for Chronic Urti-
caria and Pruritus Guidelines” in Italy12 did not distin-
guish the subtype of urticaria with spontaneously oc-
curring wheals from other types of urticaria that con-
Hide M et al.
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Table　6　Clinical questions
CQ1: Are examinations of type I allergy necessary for urticaria?
CQ2: Are general biochemical examinations necessary for urticaria?
CQ2-1: Are examinations necessary for acute urticaria?
CQ2-2: Are examinations necessary for chronic urticaria?
CQ3: Are topical steroids useful to suppress occurrence of urticaria symptoms?
CQ4:  Is local cooling, phenol and zinc oxide liniment, ointment containing antihistamines, or crotamiton useful to reduce already 
appeared symptoms of urticaria?
CQ5: May antihistamines be used for pregnant/nursing women?
CQ5-1: May antihistamines be used for pregnant women?
CQ5-2: May antihistamines be used for nursing women?
CQ6: Are steroids effective for acute urticaria?
CQ7: Are antibiotics effective for acute urticaria?
CQ8: Is it effective to increase a dose of antihistamine for chronic urticaria?
CQ9: Are supplementary medications effective for chronic urticaria when administered concurrently with antihistamines?
CQ9-1: Is the concurrent administration of H2-receptor antagonists effective for chronic urticaria?
CQ9-2: Is the concurrent administration of antileukotrienes effective for chronic urticaria?
CQ9-3: Is the concurrent administration of dapsone effective for chronic urticaria?
CQ9-4: Is the concurrent administration of glycyrrhizinic acid effective for chronic urticaria?
CQ9-5:  Is the concurrent administration of extracts of infl ammatory rabbit skin inoculated by vaccinia virus effective for chronic 
urticaria?
CQ9-6: Is the concurrent administration of tranexamic acid effective for chronic urticaria?
CQ9-7: Is the concurrent administration of Chinese herbs effective for chronic urticaria?
CQ9-8: Is the concurrent administration of anti-anxiety drugs effective for chronic urticaria?
CQ10: May continue oral steroids, if it suppresses the appearance of chronic urticaria symptoms?
CQ11: Are immunological treatments effective for chronic urticaria?
CQ11-1: Is ciclosporin effective for chronic urticaria?
CQ11-2: Are immunological treatments other than ciclosporin effective for chronic urticaria?
CQ12: Should idiopathic urticaria be treated for a certain period continuously after the disappearance of symptoms?
CQ13: Are adrenalin and steroids necessary for urticaria accompanied by anaphylactic shock?
CQ14:  Are antipyretics and analgesics without or with minimum COX1-inhibition safe for patients with aspirin-induced urticaria?
CQ15: Is a change of antihistamines effective in the treatment of dermographic urticaria?
CQ16: Are antihistamines effective for cold urticaria?
CQ17: Is cold tolerance inducible for patients with cold urticaria?
CQ18: Are antihistamines effective for solar urticaria?
CQ19: Are immunological treatments effective for solar urticaria?
CQ20: Are antihistamines effective for cholinergic urticaria?
CQ21: Does making patients actively sweat improve the symptoms of cholinergic urticaria?
CQ22: Are antihistamines effective for idiopathic angioedema?
CQ23: Is tranexamic acid effective for idiopathic angioedema?
CQ24: Is intravenous administration of C1-inhibitor effective for acute attacks of hereditary angioedema?
CQ, clinical question. Cited from reference 8.
tinued to appear for 6 weeks or longer. Recently,
Maurer and his international colleagues proposed to
use the name “chronic spontaneous urticaria”, rather
than “chronic urticaria”, and not to use “chronic idi-
opathic urticaria”.17 In Japan, the first guideline by
JDA in 2005 clearly defined “chronic urticaria” and
“acute urticaria” as subtypes of spontaneously occur-
ring urticaria.5 A minor difference between “chronic
urticaria” in the JDA guideline and “chronic sponta-
neous urticaria” in the EAACI guideline is the dura-
tion of disease. Around the world, the term “chronic”
for urticaria has been used mostly for urticaria that
continues to appear for six weeks or longer. On the
other hand, it has been widely and historically used
in Japan for urticaria appearing for not less than one
month. However the distinction between acute and
chronic urticaria was made arbitrarily and there is no
fundamental distinction between acute and chronic.18
Moreover, even one month may be too long as a pe-
riod to categorize urticarias that spontaneously occur
for days or weeks and are mostly self-remitting, apart
from those occur for months or longer and are often
Hide M et al.
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Table　7　Structured abstracts
1. Examinations for urticaria
1-1) Infectious diseases
1-2) General clinical examinations/thyroid autoimmunity
2. Antihistamines
2-1) Treatment of acute urticaria with antihistamines
2-2) Antihistamines for pregnant women
2-3) Antihistamines for nursing women
2-4) Increase in dose of antihistamines for chronic urticaria
3. Supplementary medications for chronic urticaria
3-1) H2-receptor antagonists
3-2) Antileukotrienes
3-3) Dapsone
3-4) Glycyrrhizinic acid
3-5)  Extracts of infl ammatory rabbit skin inoculated by vac-
cinia virus
3-6) Tranexamic acid
3-7) Anti-anxiety drugs
4. Experimental treatments for chronic urticaria
4-1) Ciclosporin
4-2) Intravenous immunoglobulin
4-3) Plasmapheresis
4-4) Warfarin
4-5) Methotrexate
4-6) Cyclophosphamide
4-7) Tacrolimus
4-8) Mycophenolete mofetil
4-9) Omalizumab
5. Aspirin-induced urticaria
5-1)  Safety of antipyretic analgesics with minimum COX1-
inhibition for patients with aspirin-induced urticaria
6. Treatments of physical urticaria
6-1) Antihistamines for dermographic urticaria
6-2) Antihistamines for cold urticaria
6-3) Induction of cold tolerance in cold urticaria
6-4) Antihistamines for solar urticaria
6-5) Immunosuppressants for solar urticaria
7. Treatments of cholinergic urticaria
8. Treatments of angioedema
8-1) Antihistamines
8-2) Antileukotrienes
8-3) Tranexamic acid
8-4)  Intravenous C1-inhibitor therapy for acute attacks of 
hereditary angioedema
Cited from reference 8.
refractory. In any case, nomenclature of urticaria sub-
types is still an important issue for both better prac-
tice and investigations of urticaria.19
STEROIDS
Systemic steroids are most likely used on many occa-
sions in medical practices for urticaria. They may
suppress late reactions of severe anaphylactic reac-
tions and symptoms of spontaneously occurring urti-
caria. However, the evidence for treatment with sys-
temic steroids for idiopathic (spontaneous) urticaria
is scant, especially that for long term prognosis is
poor. The 2011 JDA urticaria guideline allows for the
short term use of steroids for severe acute urticaria
with wheals covering not less than 30% of the body
surface (recommendation level C1, evidence level IV).
It also recommends not using steroids for a long time
even if some symptoms do not disappear (recommen-
dation level C2, evidence level VI). Thus, the eligibility
of steroids for urticaria is variable and should be de-
cided based on the conditions of patients, including
subtype, severity, and time course of urticaria, and
potential side effects for individual patients. Further
evidence and guidelines for more detailed usage of
steroids are expected.
OMALIZUMAB
Omalizumab is a monoclonal antibody against IgE
and currently licensed for severe asthma in a number
of countries including Japan. The effectiveness of
omalizumab for urticaria has been proven not only for
autoimmune urticaria20 in which the high affinity IgE
receptor is activated by autoantibodies, but also for a
wide range of urticarias, including physical urticarias,
cholinergic urticaria, and non-autoimmune chronic
spontaneous urticaria.21-25 An option of the treatment
with omalizumab has been included in the fourth step
of treatment for chronic urticaria in the 2009 EAACI
guideline.4 In the United States, a Phase III multicen-
ter study for chronic spontaneous urticaria resistant
to antihistamines was in progress as of 2012.21 Fur-
ther study of omalizumab may allow the expansion of
its use to severe and refractory cases of urticaria in
Japan.
CONCLUSION
Principles of the treatment and hierarchy of medica-
tions for urticaria in guidelines in Japan and those in
Europe appear in general to be the same. However,
there are still some differences between these guide-
lines, especially in terms of nomenclature and cover-
age of urticaria. It is expected that experts and or-
ganizations in this field will further cooperate, both
regionally and internationally, to find the best plat-
form for dealing with urticaria and to relieve patients
of the burdens of urticaria.
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